Enfermería
Departamento
Hospital Morales Meseguer
Murcia, EspañaPublicaciones en colaboración con investigadores/as de Hospital Morales Meseguer (70)
2024
-
Dynamic assessment of CHA2DS2-VASc and HAS-BLED scores for predicting ischemic stroke and major bleeding in atrial fibrillation patients
Revista Espanola de Cardiologia, Vol. 77, Núm. 10, pp. 835-842
-
Immune checkpoint inhibitors-associated thrombosis in patients with head and neck cancer: a study of the Spanish society of medical oncology (SEOM) thrombosis and cancer group
Clinical and Translational Oncology
-
Psychological Resilience and Suicide Attempt in Patients With Bipolar Disorder: An Exploratory Study
Journal of the American Psychiatric Nurses Association, Vol. 30, Núm. 1, pp. 44-51
-
Thrombosis in breast cancer patients on cyclin-dependent kinase inhibitors: Survival impact and predictive factors - A study by the cancer and thrombosis group of the spanish society of medical oncology (SEOM)
European Journal of Internal Medicine
2023
-
Adverse Clinical Outcomes and Associated Predictors in Rivaroxaban-Treated Atrial Fibrillation Patients With Renal Impairment
American Journal of Cardiology, Vol. 203, pp. 122-127
-
Imaging in atrial fibrillation: A way to assess atrial fibrosis and remodeling to assist decision-making
American Heart Journal, Vol. 258, pp. 1-16
-
Immune checkpoint inhibitor-associated thrombosis in patients with bladder and kidney cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group
Clinical and Translational Oncology, Vol. 25, Núm. 10, pp. 3021-3031
-
Impact of particulate matter on the incidence of atrial fibrillation and the risk of adverse clinical outcomes: A review
Science of the Total Environment, Vol. 880
-
NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy
Cell Reports Medicine, Vol. 4, Núm. 12
-
Polypharmacy and adverse events in atrial fibrillation: Main cause or reflection of multimorbidity?
Biomedicine and Pharmacotherapy, Vol. 158
-
Reducing bleeding risk in patients on oral anticoagulation therapy
Expert Review of Cardiovascular Therapy, Vol. 21, Núm. 12, pp. 923-936
-
The Atrial Fibrillation Better Care (ABC) Pathway and Clinical Outcomes in Patients with Atrial Fibrillation: the Prospective Murcia AF Project Phase II Cohort
Journal of General Internal Medicine, Vol. 38, Núm. 2, pp. 315-323
2022
-
Editorial: New horizons in the management of patients with atrial fibrillation: Interactions with the gastrointestinal system
Frontiers in Cardiovascular Medicine
-
Number needed to treat for net effect of anticoagulation in atrial fibrillation: Real-world vs. clinical-trial evidence
British Journal of Clinical Pharmacology, Vol. 88, Núm. 1, pp. 282-289
-
Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry
European heart journal. Cardiovascular pharmacotherapy, Vol. 9, Núm. 1, pp. 38-46
-
Prediction of ischemic stroke in different populations: a comparison of absolute stroke risk and CHA2DS2-VASc in real-world and clinical trial patients
European Journal of Internal Medicine
-
Relation of the ‘Atrial Fibrillation Better Care (ABC) Pathway’ to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists
Journal of Personalized Medicine, Vol. 12, Núm. 3
-
Relationship between temporal rhythm-based classification of atrial fibrillation and stroke: real-world vs. clinical trial
Journal of Thrombosis and Thrombolysis, Vol. 54, Núm. 1, pp. 1-6
2021
-
Gut microbiota and the quality of oral anticoagulation in vitamin K antagonists users: A review of potential implications
Journal of Clinical Medicine, Vol. 10, Núm. 4, pp. 1-16
-
Non-vitamin K Antagonist Oral Anticoagulants and Drug-Food Interactions: Implications for Clinical Practice and Potential Role of Probiotics and Prebiotics
Frontiers in Cardiovascular Medicine